TURBt联合术后灌注化疗治疗浅表性膀胱癌的疗效分析  

Efficacy of TURBt technique combined postoperative bladder perfusion chemotherapy on superficial bladder cancer

作　　者：龚强[1] 朱金海[1] 张小马[1] 方军[1] 

机构地区：[1]安徽省铜陵市人民医院泌尿外科,安徽铜陵244000

出　　处：《安徽医药》2014年第11期2122-2124,共3页Anhui Medical and Pharmaceutical Journal

摘　　要：目的：探讨影响原发浅表性膀胱移行细胞癌复发进展预后（指标）的主要因素。方法回顾分析153例浅表性膀胱癌患者,均采取经尿道膀胱肿瘤切除术（ TURBt）后联合膀胱灌注化疗,随访3-96个月了解复发进展情况。结果153例患者中复发58例（37.9%）,其中Ta期36例复发9例（25%）,T1期117例复发49例（41.9%）,G1期52例复发13例（25%）,G2期91例复发35例（38.5%）,G3期10例复发10例（100%）。结论浅表性膀胱癌的患者的复发进展及预后与肿瘤的体积、分期、分级、肿瘤多灶性有关,术后膀胱灌注化疗药物虽可有效降低复发率,但不同药物之间差异不明显。Objective To investigate the impact factors of recurrence and prognosis of primary superficial bladder transitional cell carci-noma. Methods Data of 153 cases of superficial bladder cancer patients were retrospectively studied, all of which adopted TURBt technique combined with intravesical chemotherapy and were followed up for an average of 3-96 months. Results There was a total of 58 cases of recurrence （37. 9%） in 153 patients,including 9 cases of recurrence in Ta phase （9/36,25%）,49 cases in T1 phase （49/117,41. 9%）,13 cases in G1 phase（13/52,25%）,35 cases in G2 phase （35/91,38. 5%）,10 cases in G3 phase（10/10, 100%） . Conclusions The main variables affecting progression and prognosis of superficial bladder cancer were tumor volume,histo-logical grade,tumor stage and tumor number. Postoperative bladder perfusion chemotherapy can effectively reduce the recurrence rate, but there were no significant differences in different drugs.

关 键 词：浅表性膀胱癌 复发 

分 类 号：R737.14[医药卫生—肿瘤]